{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:48:07Z","timestamp":1785527287146,"version":"3.56.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12500-8","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T07:16:53Z","timestamp":1785309413000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The multifaceted role of SOCS3 in colorectal cancer: molecular mechanisms and clinical implications"],"prefix":"10.1007","volume":"53","author":[{"given":"Hesan","family":"Abbasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepideh","family":"Razi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"issue":"1","key":"12500_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025. CA Cancer J Clin 75(1):10\u201345","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"12500_CR2","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/s41467-024-45960-2","volume":"15","author":"A Saeed","year":"2024","unstructured":"Saeed A, Park R, Pathak H, Al-Bzour AN, Dai J, Phadnis M et al (2024) Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort. Nat Commun 15(1):1533","journal-title":"Nat Commun"},{"issue":"5","key":"12500_CR3","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1053\/j.gastro.2015.07.011","volume":"149","author":"Y Okugawa","year":"2015","unstructured":"Okugawa Y, Grady WM, Goel A (2015) Epigenetic alterations in colorectal cancer: emerging biomarkers. Gastroenterology 149(5):1204\u201325e12","journal-title":"Gastroenterology"},{"key":"12500_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3389\/fimmu.2017.00070","volume":"8","author":"M Jiang","year":"2017","unstructured":"Jiang M, Zhang WW, Liu P, Yu W, Liu T, Yu J (2017) Dysregulation of SOCS-Mediated Negative Feedback of Cytokine Signaling in Carcinogenesis and Its Significance in Cancer Treatment. Front Immunol 8:70","journal-title":"Front Immunol"},{"key":"12500_CR5","doi-asserted-by":"publisher","first-page":"1088542","DOI":"10.3389\/fimmu.2023.1088542","volume":"14","author":"X Li","year":"2023","unstructured":"Li X, Yang Z, Chen B, Gu L, Tian G, Sui X (2023) SOCS3 as a potential driver of lung metastasis in colon cancer patients. Front Immunol 14:1088542","journal-title":"Front Immunol"},{"key":"12500_CR6","doi-asserted-by":"publisher","first-page":"112262","DOI":"10.1016\/j.biopha.2021.112262","volume":"144","author":"L Dai","year":"2021","unstructured":"Dai L, Li Z, Tao Y, Liang W, Hu W, Zhou S et al (2021) Emerging roles of suppressor of cytokine signaling 3 in human cancers. Biomed Pharmacother 144:112262","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"12500_CR7","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/carcin\/bgu017","volume":"35","author":"L Zhang","year":"2014","unstructured":"Zhang L, Li J, Li L, Zhang J, Wang X, Yang C et al (2014) IL-23 selectively promotes the metastasis of colorectal carcinoma cells with impaired Socs3 expression via the STAT5 pathway. Carcinogenesis 35(6):1330\u20131340","journal-title":"Carcinogenesis"},{"key":"12500_CR8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.gene.2017.06.013","volume":"627","author":"Q Chu","year":"2017","unstructured":"Chu Q, Shen D, He L, Wang H, Liu C, Zhang W (2017) Prognostic significance of SOCS3 and its biological function in colorectal cancer. Gene 627:114\u2013122","journal-title":"Gene"},{"key":"12500_CR9","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.2147\/CMAR.S266153","volume":"13","author":"Z Yan","year":"2021","unstructured":"Yan Z, Hong S, Song Y, Bi M (2021) microR-4449 promotes colorectal cancer cell proliferation via regulation of SOCS3 and activation of STAT3 signaling. Cancer Manag Res 13:3029\u20133039","journal-title":"Cancer Manag Res"},{"key":"12500_CR10","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.2147\/CMAR.S281925","volume":"13","author":"C Tu","year":"2021","unstructured":"Tu C, Wang Y, Cheng X, Zhu Y, Yuan W, Dong J (2021) The combination therapy of fluorouracil and oxaliplatin suppress the progression of colon cancer through mir-183-5p\/socs3 axis and downregulating PD-L1. Cancer Manag Res 13:1999\u20132008","journal-title":"Cancer Manag Res"},{"key":"12500_CR11","doi-asserted-by":"publisher","first-page":"1271102","DOI":"10.3389\/fimmu.2023.1271102","volume":"14","author":"R Pandey","year":"2023","unstructured":"Pandey R, Bakay M, Hakonarson H (2023) SOCS-JAK-STAT inhibitors and SOCS mimetics as treatment options for autoimmune uveitis, psoriasis, lupus, and autoimmune encephalitis. Front Immunol 14:1271102","journal-title":"Front Immunol"},{"issue":"6","key":"12500_CR12","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/nri2093","volume":"7","author":"A Yoshimura","year":"2007","unstructured":"Yoshimura A, Naka T, Kubo M (2007) SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 7(6):454\u2013465","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"12500_CR13","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1158\/1535-7163.MCT-22-0323","volume":"21","author":"RP Agashe","year":"2022","unstructured":"Agashe RP, Lippman SM, Kurzrock R (2022) JAK: Not Just Another Kinase. Mol Cancer Ther 21(12):1757\u20131764","journal-title":"Mol Cancer Ther"},{"key":"12500_CR14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3389\/fonc.2018.00287","volume":"8","author":"E Bousoik","year":"2018","unstructured":"Bousoik E, Montazeri Aliabadi H (2018) Do We Know Jack About JAK? A Closer Look at JAK\/STAT Signaling Pathway. Front Oncol 8:287","journal-title":"Front Oncol"},{"key":"12500_CR15","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.2147\/JIR.S353489","volume":"15","author":"T Mengie Ayele","year":"2022","unstructured":"Mengie Ayele T, Tilahun Muche Z, Behaile Teklemariam A, Bogale Kassie A, Chekol Abebe E (2022) Role of JAK2\/STAT3 signaling pathway in the tumorigenesis, chemotherapy resistance, and treatment of solid tumors: a systemic review. J Inflamm Res 15:1349\u20131364","journal-title":"J Inflamm Res"},{"key":"12500_CR16","doi-asserted-by":"publisher","first-page":"1023177","DOI":"10.3389\/fonc.2022.1023177","volume":"12","author":"B Huang","year":"2022","unstructured":"Huang B, Lang X, Li X (2022) The role of IL-6\/JAK2\/STAT3 signaling pathway in cancers. Front Oncol 12:1023177","journal-title":"Front Oncol"},{"issue":"12","key":"12500_CR17","doi-asserted-by":"publisher","first-page":"16667","DOI":"10.18632\/aging.203186","volume":"13","author":"M Zhuang","year":"2021","unstructured":"Zhuang M, Ding X, Song W, Chen H, Guan H, Yu Y et al (2021) Correlation of IL-6 and JAK2\/STAT3 signaling pathway with prognosis of nasopharyngeal carcinoma patients. Aging 13(12):16667\u201316683","journal-title":"Aging"},{"issue":"4","key":"12500_CR18","doi-asserted-by":"publisher","first-page":"e25045","DOI":"10.4161\/jkst.25045","volume":"2","author":"CA White","year":"2013","unstructured":"White CA, Nicola NA (2013) SOCS3: An essential physiological inhibitor of signaling by interleukin-6 and G-CSF family cytokines. Jak-Stat 2(4):e25045","journal-title":"Jak-Stat"},{"issue":"4","key":"12500_CR19","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.4049\/jimmunol.179.4.2170","volume":"179","author":"Y Matsumura","year":"2007","unstructured":"Matsumura Y, Kobayashi T, Ichiyama K, Yoshida R, Hashimoto M, Takimoto T et al (2007) Selective expansion of foxp3-positive regulatory T cells and immunosuppression by suppressors of cytokine signaling 3-deficient dendritic cells. J Immunol 179(4):2170\u20132179","journal-title":"J Immunol"},{"issue":"4","key":"12500_CR20","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.bbrc.2003.09.140","volume":"310","author":"K Yamamoto","year":"2003","unstructured":"Yamamoto K, Yamaguchi M, Miyasaka N, Miura O (2003) SOCS-3 inhibits IL-12-induced STAT4 activation by binding through its SH2 domain to the STAT4 docking site in the IL-12 receptor \u03b22 subunit. Biochem Biophys Res Commun 310(4):1188\u20131193","journal-title":"Biochem Biophys Res Commun"},{"key":"12500_CR21","doi-asserted-by":"publisher","first-page":"727987","DOI":"10.3389\/fmed.2021.727987","volume":"8","author":"ML Sobah","year":"2021","unstructured":"Sobah ML, Liongue C, Ward AC (2021) SOCS proteins in immunity, inflammatory diseases, and immune-related cancer. Front Med (Lausanne) 8:727987","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"12500_CR22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/imr.12305","volume":"266","author":"EM Linossi","year":"2015","unstructured":"Linossi EM, Nicholson SE (2015) Kinase inhibition, competitive binding and proteasomal degradation: resolving the molecular function of the suppressor of cytokine signaling (SOCS) proteins. Immunol Rev 266(1):123\u2013133","journal-title":"Immunol Rev"},{"key":"12500_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cellimm.2016.07.002","volume":"306\u2013307","author":"FM Ghazawi","year":"2016","unstructured":"Ghazawi FM, Faller EM, Parmar P, El-Salfiti A, MacPherson PA (2016) Suppressor of cytokine signaling (SOCS) proteins are induced by IL-7 and target surface CD127 protein for degradation in human CD8 T cells. Cell Immunol 306\u2013307:41\u201352","journal-title":"Cell Immunol"},{"issue":"5","key":"12500_CR24","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0092-8674(00)80049-5","volume":"98","author":"J-C Marine","year":"1999","unstructured":"Marine J-C, McKay C, Wang D, Topham DJ, Parganas E, Nakajima H et al (1999) SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell 98(5):617\u2013627","journal-title":"Cell"},{"issue":"24","key":"12500_CR25","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1161\/CIRCULATIONAHA.111.028498","volume":"124","author":"T Yajima","year":"2011","unstructured":"Yajima T, Murofushi Y, Zhou H, Park S, Housman J, Zhong Z-H et al (2011) Absence of SOCS3 in the cardiomyocyte increases mortality in a gp130-dependent manner accompanied by contractile dysfunction and ventricular arrhythmias. Circulation 124(24):2690\u20132701","journal-title":"Circulation"},{"issue":"2","key":"12500_CR26","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.4081\/ejh.2013.e19","volume":"57","author":"S San Martin","year":"2013","unstructured":"San Martin S, Fitzgerald JS, Weber M, P\u00e1rraga M, S\u00e1ez T, Zorn TM et al (2013) Stat3 and Socs3 expression patterns during murine placenta development. Eur J Histochem 57(2):e19","journal-title":"Eur J Histochem"},{"issue":"4","key":"12500_CR27","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1097-2765(00)80062-3","volume":"1","author":"C Bj\u00f8rb\u00e6k","year":"1998","unstructured":"Bj\u00f8rb\u00e6k C, Elmquist JK, Frantz JD, Shoelson SE, Flier JS (1998) Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol Cell 1(4):619\u2013625","journal-title":"Mol Cell"},{"issue":"1","key":"12500_CR28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.2337\/db12-0443","volume":"62","author":"SB Jorgensen","year":"2013","unstructured":"Jorgensen SB, O\u2019Neill HM, Sylow L, Honeyman J, Hewitt KA, Palanivel R et al (2013) Deletion of skeletal muscle SOCS3 prevents insulin resistance in obesity. Diabetes 62(1):56\u201364","journal-title":"Diabetes"},{"issue":"9b","key":"12500_CR29","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.1111\/j.1582-4934.2009.00661.x","volume":"13","author":"H Xiong","year":"2009","unstructured":"Xiong H, Chen ZF, Liang QC, Du W, Chen HM, Su WY et al (2009) Inhibition of DNA methyltransferase induces G2 cell cycle arrest and apoptosis in human colorectal cancer cells via inhibition of JAK2\/STAT3\/STAT5 signalling. J Cell Mol Med 13(9b):3668\u20133679","journal-title":"J Cell Mol Med"},{"issue":"22","key":"12500_CR30","doi-asserted-by":"publisher","first-page":"15984","DOI":"10.18632\/oncotarget.23477","volume":"9","author":"X Dong","year":"2018","unstructured":"Dong X, Wang J, Tang B, Hao YX, Li PY, Li SY et al (2018) The role and gene expression profile of SOCS3 in colorectal carcinoma. Oncotarget 9(22):15984\u201315996","journal-title":"Oncotarget"},{"issue":"1","key":"12500_CR31","first-page":"43","volume":"39","author":"Z Hong","year":"2019","unstructured":"Hong Z, Zhang X (2019) [Role of cytokine signal suppressor 3 in the regulatory mechanism of colon cancer invasion and proliferation]. Nan Fang Yi Ke Da Xue Xue Bao 39(1):43\u201348","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"issue":"8","key":"12500_CR32","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.4161\/epi.6.8.16167","volume":"6","author":"S Wilop","year":"2011","unstructured":"Wilop S, van Gemmeren TB, Lentjes MH, van Engeland M, Herman JG, Br\u00fcmmendorf TH et al (2011) Methylation-associated dysregulation of the suppressor of cytokine signaling-3 gene in multiple myeloma. Epigenetics 6(8):1047\u20131052","journal-title":"Epigenetics"},{"key":"12500_CR33","doi-asserted-by":"publisher","first-page":"108913","DOI":"10.1016\/j.biopha.2019.108913","volume":"115","author":"K Liu","year":"2019","unstructured":"Liu K, Wu Z, Chu J, Yang L, Wang N (2019) Promoter methylation and expression of SOCS3 affect the clinical outcome of pediatric acute lymphoblastic leukemia by JAK\/STAT pathway. Biomed Pharmacother 115:108913","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"12500_CR34","first-page":"1201","volume":"36","author":"JC Cooper","year":"2010","unstructured":"Cooper JC, Shi M, Chueh F-Y, Venkitachalam S, Yu C-L (2010) Enforced SOCS1 and SOCS3 expression attenuates Lck-mediated cellular transformation. Int J Oncol 36(5):1201\u20131208","journal-title":"Int J Oncol"},{"issue":"1","key":"12500_CR35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-016-0300-3","volume":"9","author":"Y-x Liu","year":"2016","unstructured":"Liu Y-x, Wang L, Liu W-j, Zhang H-t, Xue J-h, Zhang Z-w et al (2016) MiR-124-3p\/B4GALT1 axis plays an important role in SOCS3-regulated growth and chemo-sensitivity of CML. J Hematol Oncol 9(1):69","journal-title":"J Hematol Oncol"},{"issue":"10","key":"12500_CR36","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.3390\/cancers14102549","volume":"14","author":"R Masuzaki","year":"2022","unstructured":"Masuzaki R, Kanda T, Sasaki R, Matsumoto N, Nirei K, Ogawa M, Karp SJ, Moriyama M, Kogure H (2022) Suppressors of Cytokine Signaling and Hepatocellular Carcinoma. Cancers (Basel) 14(10):2549. PMID: 35626153; PMCID: PMC9139988 https:\/\/doi.org\/10.3390\/cancers14102549","journal-title":"Cancers (Basel)"},{"issue":"22","key":"12500_CR37","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.1158\/0008-5472.CAN-22-1203","volume":"82","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Li Y, Shi D, Wang X, Dai S, Yang M et al (2022) MEX3C-Mediated Decay of SOCS3 mRNA Promotes JAK2\/STAT3 Signaling to Facilitate Metastasis in Hepatocellular Carcinoma. Cancer Res 82(22):4191\u20134205","journal-title":"Cancer Res"},{"issue":"21","key":"12500_CR38","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1080\/15384101.2020.1824717","volume":"19","author":"Z Li","year":"2020","unstructured":"Li Z, Zheng J, Lin W, Weng J, Hong W, Zou J et al (2020) Circular RNA hsa_circ_0001785 inhibits the proliferation, migration and invasion of breast cancer cells in vitro and in vivo by sponging miR-942 to upregulate SOCS3. Cell Cycle 19(21):2811\u20132825","journal-title":"Cell Cycle"},{"issue":"3","key":"12500_CR39","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41419-019-1382-y","volume":"10","author":"J-Z Xu","year":"2019","unstructured":"Xu J-Z, Shao C-C, Wang X-J, Zhao X, Chen J-Q, Ouyang Y-X et al (2019) circTADA2As suppress breast cancer progression and metastasis via targeting miR-203a-3p\/SOCS3 axis. Cell Death Dis 10(3):175","journal-title":"Cell Death Dis"},{"issue":"11","key":"12500_CR40","doi-asserted-by":"publisher","first-page":"10896","DOI":"10.18632\/aging.103303","volume":"12","author":"M Chen","year":"2020","unstructured":"Chen M, Zeng J, Chen S, Li J, Wu H, Dong X et al (2020) SPTBN1 suppresses the progression of epithelial ovarian cancer via SOCS3-mediated blockade of the JAK\/STAT3 signaling pathway. Aging 12(11):10896","journal-title":"Aging"},{"issue":"15","key":"12500_CR41","doi-asserted-by":"publisher","first-page":"19760","DOI":"10.18632\/aging.203388","volume":"13","author":"W Liu","year":"2021","unstructured":"Liu W, Long Q, Zhang W, Zeng D, Hu B, Liu S et al (2021) miRNA-221-3p derived from M2-polarized tumor-associated macrophage exosomes aggravates the growth and metastasis of osteosarcoma through SOCS3\/JAK2\/STAT3 axis. Aging 13(15):19760\u201319775","journal-title":"Aging"},{"key":"12500_CR42","doi-asserted-by":"publisher","first-page":"119501","DOI":"10.1016\/j.lfs.2021.119501","volume":"277","author":"Y Hu","year":"2021","unstructured":"Hu Y, Luo X, Zhou J, Chen S, Gong M, Deng Y et al (2021) Piperlongumine inhibits the progression of osteosarcoma by downregulating the SOCS3\/JAK2\/STAT3 pathway via miR-30d-5p. Life Sci 277:119501","journal-title":"Life Sci"},{"issue":"1","key":"12500_CR43","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12575-025-00296-z","volume":"27","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Chu M, Ye M, Yin Y, Chen H (2025) SOCS3: An Immunological Biomarker Offering Potential Therapeutic Targets for Malignant Tumors. Biol Proced Online 27(1):36","journal-title":"Biol Proced Online"},{"issue":"2","key":"12500_CR44","doi-asserted-by":"publisher","first-page":"167578","DOI":"10.1016\/j.bbadis.2024.167578","volume":"1871","author":"P Zhang","year":"2025","unstructured":"Zhang P, Pei B, Yi C, Akanyibah FA, Mao F (2025) The role of suppressor of cytokine signaling 3 in inflammatory bowel disease and its associated colorectal cancer. Biochim Biophys Acta Mol Basis Dis 1871(2):167578","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"1","key":"12500_CR45","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3892\/or.2013.2858","volume":"31","author":"X Wei","year":"2014","unstructured":"Wei X, Wang G, Li W, Hu X, Huang Q, Xu K et al (2014) Activation of the JAK-STAT3 pathway is associated with the growth of colorectal carcinoma cells. Oncol Rep 31(1):335\u2013341","journal-title":"Oncol Rep"},{"issue":"3","key":"12500_CR46","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.4049\/jimmunol.0801217","volume":"184","author":"S Matsumoto","year":"2010","unstructured":"Matsumoto S, Hara T, Mitsuyama K, Yamamoto M, Tsuruta O, Sata M et al (2010) Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6\/soluble\u2013IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol 184(3):1543\u20131551","journal-title":"J Immunol"},{"key":"12500_CR47","doi-asserted-by":"publisher","first-page":"147357","DOI":"10.1016\/j.gene.2023.147357","volume":"868","author":"J Rong","year":"2023","unstructured":"Rong J, Pu R, Sun H, Liu Y, Tian T, Bi H et al (2023) Association between the methylation of CpG islands in JAK-STAT pathway-related genes and colorectal cancer. Gene 868:147357","journal-title":"Gene"},{"issue":"12","key":"12500_CR48","doi-asserted-by":"publisher","first-page":"9913","DOI":"10.1007\/s11033-020-05949-8","volume":"47","author":"P Pourdavoud","year":"2020","unstructured":"Pourdavoud P, Pakzad B, Mosallaei M, Saadatian Z, Esmaeilzadeh E, Alimolaie A et al (2020) MiR-196: emerging of a new potential therapeutic target and biomarker in colorectal cancer. Mol Biol Rep 47(12):9913\u20139920","journal-title":"Mol Biol Rep"},{"key":"12500_CR49","doi-asserted-by":"publisher","first-page":"881801","DOI":"10.3389\/fonc.2022.881801","volume":"12","author":"L Dai","year":"2022","unstructured":"Dai L, Tao Y, Shi Z, Liang W, Hu W, Xing Z et al (2022) SOCS3 acts as an onco-immunological biomarker with value in assessing the tumor microenvironment, pathological staging, histological subtypes, therapeutic effect, and prognoses of several types of cancer. Front Oncol 12:881801","journal-title":"Front Oncol"},{"key":"12500_CR50","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.3389\/fimmu.2020.01624","volume":"11","author":"NA Johdi","year":"2020","unstructured":"Johdi NA, Sukor NF (2020) Colorectal Cancer Immunotherapy: Options and Strategies. Front Immunol 11:1624. PMID: 33042104; PMCID: PMC7530194 https:\/\/doi.org\/10.3389\/fimmu.2020.01624","journal-title":"Front Immunol"},{"issue":"8","key":"12500_CR51","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3390\/biomedicines9081016","volume":"9","author":"AN Gargalionis","year":"2021","unstructured":"Gargalionis AN, Papavassiliou KA, Papavassiliou AG (2021) Targeting STAT3 Signaling Pathway in Colorectal Cancer. Biomedicines 9(8):1016. PMID: 34440220; PMCID: PMC8392110 https:\/\/doi.org\/10.3390\/biomedicines9081016","journal-title":"Biomedicines"},{"key":"12500_CR52","doi-asserted-by":"publisher","first-page":"1507621","DOI":"10.3389\/fcell.2024.1507621","volume":"12","author":"P Li","year":"2024","unstructured":"Li P, Huang D (2024) Targeting the JAK-STAT pathway in colorectal cancer: mechanisms, clinical implications, and therapeutic potential. Front Cell Dev Biol 12:1507621","journal-title":"Front Cell Dev Biol"},{"issue":"30","key":"12500_CR53","doi-asserted-by":"publisher","first-page":"49807","DOI":"10.18632\/oncotarget.17971","volume":"8","author":"D Ren","year":"2017","unstructured":"Ren D, Lin B, Zhang X, Peng Y, Ye Z, Ma Y et al (2017) Maintenance of cancer stemness by miR-196b-5p contributes to chemoresistance of colorectal cancer cells via activating STAT3 signaling pathway. Oncotarget 8(30):49807\u201349823","journal-title":"Oncotarget"},{"issue":"10","key":"12500_CR54","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1093\/carcin\/bgs214","volume":"33","author":"Y Li","year":"2012","unstructured":"Li Y, Deuring J, Peppelenbosch MP, Kuipers EJ, de Haar C, van der Woude CJ (2012) IL-6-induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer. Carcinogenesis 33(10):1889\u20131896","journal-title":"Carcinogenesis"},{"key":"12500_CR55","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/mc.20777","volume":"51","author":"H Xiong","year":"2012","unstructured":"Xiong H, Du W, Zhang Y-J, Hong J, Su W-Y, Tang J-T et al (2012) Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2\/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells. Mol Carcinog 51:174\u2013184","journal-title":"Mol Carcinog"},{"key":"12500_CR56","doi-asserted-by":"publisher","first-page":"183","DOI":"10.32471\/exp-oncology.2312-8852.vol-42-no-3.15113","volume":"42","author":"M Sanaei","year":"2020","unstructured":"Sanaei M, Kavoosi F, Behjoo H (2020) Effect of valproic acid and zebularine on SOCS-1 and SOCS-3 gene expression in colon carcinoma SW48 cell line. Exp Oncol 42:183\u2013187","journal-title":"Exp Oncol"},{"issue":"10","key":"12500_CR57","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s12032-024-02481-8","volume":"41","author":"ZE Hunzeker","year":"2024","unstructured":"Hunzeker ZE, Zhao L, Kim AM, Parker JM, Zhu Z, Xiao H et al (2024) The role of IL-22 in cancer. Med Oncol 41(10):240","journal-title":"Med Oncol"},{"issue":"1","key":"12500_CR58","doi-asserted-by":"publisher","first-page":"G93","DOI":"10.1152\/ajpgi.00074.2021","volume":"322","author":"H Han","year":"2022","unstructured":"Han H, Davidson LA, Fan YY, Landrock KK, Jayaraman A, Safe SH et al (2022) Loss of aryl hydrocarbon receptor suppresses the response of colonic epithelial cells to IL22 signaling by upregulating SOCS3. Am J Physiol Gastrointest Liver Physiol 322(1):G93\u2013g106","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"12500_CR59","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3390\/receptors2010005","volume":"2","author":"S Safe","year":"2023","unstructured":"Safe S, Han H, Jayaraman A, Davidson LA, Allred CD, Ivanov I et al (2023) Aryl hydrocarbon receptor (AhR) signaling in colonic cells and tumors. Receptors (Basel) 2(1):93\u201399","journal-title":"Receptors (Basel)"},{"issue":"3","key":"12500_CR60","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3390\/cancers16030472","volume":"16","author":"BD Griffith","year":"2024","unstructured":"Griffith BD, Frankel TL (2024) The Aryl Hydrocarbon Receptor: Impact on the Tumor Immune Microenvironment and Modulation as a Potential Therapy. Cancers (Basel) 16(3):472. PMID: 38339226; PMCID: PMC10854841 https:\/\/doi.org\/10.3390\/cancers16030472","journal-title":"Cancers (Basel)"},{"issue":"8","key":"12500_CR61","doi-asserted-by":"publisher","first-page":"112940","DOI":"10.1016\/j.celrep.2023.112940","volume":"42","author":"S Mise-Omata","year":"2023","unstructured":"Mise-Omata S, Ando M, Srirat T, Nakagawara K, Hayakawa T, Iizuka-Koga M et al (2023) SOCS3 deletion in effector T cells confers an anti-tumorigenic role of IL-6 to the pro-tumorigenic cytokine. Cell Rep 42(8):112940","journal-title":"Cell Rep"},{"issue":"1","key":"12500_CR62","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12935-024-03315-3","volume":"24","author":"T Chen","year":"2024","unstructured":"Chen T, Wang M, Chen Y, Liu Y (2024) Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors. Cancer Cell Int 24(1):133","journal-title":"Cancer Cell Int"},{"issue":"3","key":"12500_CR63","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00281-024-01013-w","volume":"46","author":"AD Hughes","year":"2024","unstructured":"Hughes AD, Teachey DT, Diorio C (2024) Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy. Semin Immunopathol 46(3):5","journal-title":"Semin Immunopathol"},{"issue":"24","key":"12500_CR64","doi-asserted-by":"publisher","first-page":"13656","DOI":"10.3390\/ijms252413656","volume":"25","author":"Y Qi","year":"2024","unstructured":"Qi Y, Ma Y, Duan G (2024) Pharmacological Mechanisms of Bile Acids Targeting the Farnesoid X Receptor. Int J Mol Sci 25(24):13656. PMID: 39769418; PMCID: PMC11727972 https:\/\/doi.org\/10.3390\/ijms252413656","journal-title":"Int J Mol Sci"},{"issue":"2","key":"12500_CR65","doi-asserted-by":"publisher","first-page":"e170428","DOI":"10.1172\/jci.insight.170428","volume":"9","author":"X Dong","year":"2024","unstructured":"Dong X, Qi M, Cai C, Zhu Y, Li Y, Coulter S, Sun F, Liddle C, Uboha NV, Halberg R, Xu W, Marker P, Fu T (2024) Farnesoid X receptor mediates macrophage-intrinsic responses to suppress colitis-induced colon cancer progression. JCI Insight 9(2):e170428. PMID: 38258906; PMCID: PMC10906220 https:\/\/doi.org\/10.1172\/jci.insight.170428","journal-title":"JCI Insight"},{"issue":"4","key":"12500_CR66","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s13402-024-00920-2","volume":"47","author":"W Zhang","year":"2024","unstructured":"Zhang W, Qin X, Zhang K, Ma J, Li M, Jin G et al (2024) Microbial metabolite trimethylamine-N-oxide induces intestinal carcinogenesis through inhibiting farnesoid X receptor signaling. Cell Oncol (Dordr) 47(4):1183\u20131199","journal-title":"Cell Oncol (Dordr)"},{"issue":"24","key":"12500_CR67","doi-asserted-by":"publisher","first-page":"14549","DOI":"10.1111\/jcmm.16083","volume":"24","author":"S Li","year":"2020","unstructured":"Li S, Xu Z, Guo J, Zheng J, Sun X, Yu J (2020) Farnesoid X receptor activation induces antitumour activity in colorectal cancer by suppressing JAK2\/STAT3 signalling via transactivation of SOCS3 gene. J Cell Mol Med 24(24):14549\u201314560","journal-title":"J Cell Mol Med"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12500-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12500-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12500-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:11:01Z","timestamp":1785521461000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12500-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12500"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12500-8","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"28 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors reviewed and approved the final version of the manuscript.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1293"}}